Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
about
Cytotoxic and targeted therapy for hereditary cancersActivated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Pediatric Medullary Thyroid CarcinomaMilestones in the curability of pediatric cancersComprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.The discovery and development of vandetanib for the treatment of thyroid cancer.Vandetanib for the treatment of thyroid cancer: an update.Novel therapies for thyroid cancer.Selective use of vandetanib in the treatment of thyroid cancer.Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Management of hereditary medullary thyroid carcinoma.The safety of vandetanib for the treatment of thyroid cancer.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Advances in small molecule therapy for treating metastatic thyroid cancer.Personalization of targeted therapy in advanced thyroid cancer.Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis.
P2860
Q26739366-1D9C34BC-DB3D-445D-901C-CED415E40EA1Q33757079-87562295-0B35-4977-A597-BBF245AA5922Q34131012-5B4FB9B8-01BC-4B01-9E44-FA34CE7FBC61Q34468665-3F88928D-B05E-4D5A-ADF1-D22C2362F2C2Q34543413-D457CAB0-85BF-4265-A8AE-71C6F2A86A8DQ35070321-7E9564F3-275C-4CB4-A8E6-F420A73EFDA5Q35224485-0336CD8D-772E-498F-B000-7A9739D1678BQ35396089-F61E644C-4FFA-4040-BF81-7CA0DE7A5AF8Q35599600-597922CC-6918-42C3-BE96-669FEFDA0C5FQ36509363-E31C4070-63C6-4C16-9F88-BDF3858F06F1Q36715586-57F6D238-D295-4019-8CE8-BCB47F6ECBBDQ36925083-DBF0E9C4-86E5-4B83-A9CD-333F40D21414Q37009001-4DA487EB-6500-451B-B8FD-CE6D32BBF565Q37327513-81B3967A-FA54-4F97-8025-248AAFAEB9F2Q38168304-375741DA-B288-435D-B3AC-54AF0C623560Q38185691-CA185048-F5EF-4106-9D91-4FB74902EDF8Q38260495-01EC54BE-C8F3-4061-93D5-CB7E605282D5Q38546474-60F6D42B-6E75-4169-8004-A354CF84EC1BQ38588103-64F00FE7-5BFB-4809-AC84-48215B186434Q38625034-AE626D6A-7E86-41B0-B3E0-4F05BAC74C8FQ38721033-766A247C-35AF-41A9-A1B3-A7EB6F193BF0Q38864998-FA6F8BD1-94B6-4D5A-8B7F-72D1F9E36EAFQ38883187-A0F10C44-1984-4659-8869-361B49627CB1Q38960074-0D5BA5AD-EF0E-43EE-ABD6-A981C7598763Q39364787-6B1B82A2-9B52-44B9-98FC-737CE921FFD7Q40922523-8DFCE600-6EF4-4C7A-BDD5-1BA4CDFC1827Q47395532-5D7DC530-390C-4820-AAE4-586A80316951Q47601932-AC120650-A3E9-40B5-989C-DE5DED2BE75EQ47804358-D6774B59-B169-40AE-ACDA-BD64754B7DE9Q49244147-94402436-63DE-4806-9581-8A2823C4CA9BQ50918579-967E76D2-AA5C-4F46-9FCF-F498867AAAFBQ54338133-149092E2-E71A-43A6-BFDE-CA8C93DF49B1Q54978829-E64AE619-0B73-4185-8857-5E6F7732B2F9
P2860
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@ast
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@en
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@nl
type
label
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@ast
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@en
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@nl
prefLabel
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@ast
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@en
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@nl
P2093
P2860
P1476
Vandetanib in children and ado ...... d medullary thyroid carcinoma.
@en
P2093
Alberta Aikin
Brigitte C Widemann
Elizabeth Fox
Frank M Balis
Leigh Marcus
Maria J Merino
Maya Lodish
Meredith K Chuk
Patricia O Whitcomb
P2860
P304
P356
10.1158/1078-0432.CCR-13-0071
P407
P577
2013-06-13T00:00:00Z